StockNews.AI
BPMC
StockNews.AI
78 days

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

1. BPMC to be acquired by Sanofi for $129 per share. 2. Shareholders will receive contingent value rights for BLU-808 milestones. 3. Investigation launched into potential board fiduciary duty breaches. 4. Analyst sets a $167 price target, raising acquisition concerns. 5. Termination fee limits board's ability to seek better offers.

M&A
+0.02%Current Return
VS
+0.77%S&P 500
$127.5806/02 02:49 PM EDTEvent Start
$127.606/03 09:12 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bearish?

The proposed acquisition price is below analyst targets, indicating undervaluation concerns. Historical acquisitions have often seen price corrections post-announcement if perceived as low.

How important is it?

The article discusses an ongoing acquisition and legal investigation, both pivotal for BPMC's stock. High stakes involve shareholder dissatisfaction and potential legal ramifications affecting stock price.

Why Short Term?

Immediate investor reactions can affect stock price during the acquisition acceptance period. Past examples show significant stock volatility around acquisition announcements.

Related Companies

SNYAMGNGILD
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY). On June 2, 2025, Blueprint Medicines announced the execution of a definitive agreement with Sanofi for the acquisition of all outstanding shares of Blueprint Medicines for $129.00 per share in cash. Whereas shareholders also will receive one non-tradeable contingent value right which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The transaction agreement between Blueprint and Sanofi contains a provision that unreasonably constrains Blueprint’s ability to solicit or accept superior proposals by imposing a substantial termination fee should the board elect to pursue a competing bid. Moreover, one Wall Street analyst has set a $167 per share price target for Blueprint’s common stock—markedly above the agreed transaction price. You can click or copy and paste the following link to join this investigation: https://www.johnsonfistel.com/investigations/blueprint-medicines-corporation If you are a shareholder of Blueprint Medicines and believe the proposed buyout price is too low or if you're interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If emailing, please include a phone number. About Johnson Fistel, PLLP | Top Law Firm for Securities Fraud and Investors Rights:Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay informed about stock-related developments and learn how Johnson Fistel, PLLP may help you recover investment losses. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Achievements: In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs’ securities law firm in the United States, as determined by the total dollar value of final recoveries. Attorney advertising.Past results do not guarantee future outcomes.Services may be performed by attorneys in any of our offices.Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content. Contact: Johnson Fistel, PLLP501 W. Broadway, Suite 800, San Diego, CA 92101James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471jimb@johnsonfistel.com or fjohnson@johnsonfistel.com 

Related News